Itraconazole and Antidiabetic Medication Interactions: Cited Evidence

Sulfonylureas

• Sulfonylureas inherently carry a risk of hypoglycemia, which is amplified when they are combined with other glucose‑lowering agents. [1][2]

DPP‑4 Inhibitors

• DPP‑4 inhibitors have minimal hypoglycemia risk as monotherapy and are not significantly metabolized by CYP3A4; therefore, itraconazole does not produce a clinically relevant pharmacokinetic interaction. [1][3]
• Most DPP‑4 inhibitors require renal dose adjustment (except linagliptin), and this requirement is independent of itraconazole co‑administration. 1

SGLT2 Inhibitors

• SGLT2 inhibitors are not metabolized via CYP3A4 and show no direct pharmacokinetic interaction with itraconazole. [4][5]
• Standard monitoring for SGLT2 inhibitors—assessment for volume depletion, genital mycotic infections, and renal function—remains unchanged when itraconazole is added. [3][6]

GLP‑1 Receptor Agonists

• GLP‑1 receptor agonists, administered subcutaneously as peptides, are unaffected by CYP3A4 inhibition and thus have no interaction with itraconazole. [1][2]
• When combined with insulin or sulfonylureas, GLP‑1 receptor agonists increase the potential for hypoglycemia, an effect that is unrelated to itraconazole use. [1][7]

Thiazolidinediones (TZDs)

• TZDs require routine monitoring for fluid retention, heart‑failure signs, and fracture risk; itraconazole does not alter these safety considerations. [1][2]

Patients with Renal Impairment

• In individuals with reduced estimated glomerular filtration rate, both metformin and itraconazole need dose adjustments to avoid accumulation and toxicity. 4

Combination Antidiabetic Therapy

• The cumulative hypoglycemia risk associated with multiple antidiabetic agents—particularly insulin plus sulfonylureas—is independent of itraconazole co‑administration, but warrants vigilant glucose monitoring. [8][9]